Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures (2015 - 2025)

Ocular Therapeutix's quarterly Gains from Sales and Divestitures came in at $1.6 million in Q4 2025, up 21.47% year-on-year from $1.3 million in Q4 2024, and up 21.47% quarter-over-quarter from $1.3 million in Q4 2024.

Ocular Therapeutix has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $1.6 million in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 21.47% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $1.6 million (up 21.47% YoY), and the FY2025 full-year result was $1.6 million, up 21.47% from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 stood at $1.6 million, up from $1.3 million in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.6 million in Q4 2025, with the low at $393805.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 3 years is $1.1 million, with a median of $1.3 million recorded in 2024.
  • Year-over-year, Gains from Sales and Divestitures surged 224.37% in 2024 and advanced 21.47% in 2025.
  • Tracing OCUL's Gains from Sales and Divestitures over 3 years: stood at $393805.0 in 2023, then surged by 224.37% to $1.3 million in 2024, then grew by 21.47% to $1.6 million in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $1.6 million (Q4 2025), $1.3 million (Q4 2024), and $393805.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Ocular Therapeutix 1.99 Bn 1.99 Bn 9.46 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.55 Mn
Dec 31, 2025 1.55 Mn
Dec 31, 2024 1.28 Mn
Dec 31, 2024 1.28 Mn
Dec 31, 2023 393,805.00
Dec 31, 2023 393,805.00
Dec 31, 2015 28,437.00
Dec 31, 2015 28,437.00